Keryx Biopharmaceuticals Inc (KERX)

5.98
0.33 5.84
NASDAQ : Health Care
Prev Close 5.65
Open 5.53
Day Low/High 5.48 / 6.00
52 Wk Low/High 2.80 / 9.49
Volume 1.44M
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 107.67M
Market Cap 594.33M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Keryx Biopharmaceuticals is Now Oversold (KERX)

Keryx Biopharmaceuticals is Now Oversold (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of KERX February 2017 Options Trading

First Week Of KERX February 2017 Options Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the February 2017 expiration.

Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week

Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week

Majority of patients when started on Auryxia achieved target serum phosphorus levels within six months of treatment

January 2019 Options Now Available For Keryx Biopharmaceuticals (KERX)

January 2019 Options Now Available For Keryx Biopharmaceuticals (KERX)

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2019 expiration.

Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)

Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)

Auryxia is now available for prescription in the U.S.

Keryx Biopharmaceuticals Announces Presentations Of Data At The American Society Of Nephrology Kidney Week 2016 Annual Meeting

Keryx Biopharmaceuticals Announces Presentations Of Data At The American Society Of Nephrology Kidney Week 2016 Annual Meeting

First presentation of data at a medical conference from pivotal Phase 3 study evaluating ferric citrate as a treatment for iron deficiency anemia in adults with stage 3-5 chronic kidney disease

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Shares of Omeros fell almost 10% after analysts' downgraded the biotech.

October 3rd Deadline Alert: GPM Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. And Announces Expanded Class Period

October 3rd Deadline Alert: GPM Reminds Investors Of The Upcoming Deadline In The Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. And Announces Expanded Class Period

Glancy Prongay & Murray LLP ("GPM") reminds investors of the October 3, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired...

KERX Crosses Above Key Moving Average Level

KERX Crosses Above Key Moving Average Level

In trading on Thursday, shares of Keryx Biopharmaceuticals Inc. crossed above their 200 day moving average of $4.99, changing hands as high as $5.05 per share.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc.